Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Mellalta Meets LLP | PRODUCT CODE: 1634586

Cover Image

PUBLISHER: Mellalta Meets LLP | PRODUCT CODE: 1634586

TP53 mutant high-grade transitional cell bladder cancer | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

PUBLISHED:
PAGES: 150 Pages
DELIVERY TIME: 5-7 business days
SELECT AN OPTION
PPT (Single User License)
USD 5900
PPT (2 - 3 User License)
USD 6500
PPT (Site License - Up to 10 Users)
USD 9900
PPT (Enterprise License)
USD 14999

Add to Cart

The tumor protein-coding gene TP53 is one of the most frequently occurring mutant genes in bladder cancer. The tumor protein p53 (TP53), a tumor suppressor, is now understood to exist in various tumor types. It can regulate the target gene's expression in order to manage the intricate cellular processes that result in transcriptional activation, senescence, apoptosis, metabolic changes, and cell cycle. Around 275,000 people worldwide receive a bladder cancer diagnosis each year, and 108,000 people die from the disease. In industrialized countries, TCC accounts for 90% of bladder cancers. The majority of bladder cancers in developing countries, particularly in the Middle East and Africa, are SCCs, and the majority of these cancers are caused by infection with Schistosoma haematobium. The potential target drugs mitomycin-C, doxorubicin, and gemcitabine are highly sensitive to bladder cancer cells that carry TP53 mutations but not to other types of tumors. Mitomycin-C, doxorubicin, and gemcitabine thus provided the possibility of individualized compounds for bladder cancer patients with TP53 mutations.

Description

The tumor protein is encoded by the mutant gene TP53, which is one of the most common in bladder cancer. It is now understood that various tumor types contain the tumor protein p53 (TP53), which functions as a tumor suppressor. It can regulate the target gene's expression in order to manage the intricate cellular processes that result in transcriptional activation, senescence, apoptosis, metabolic changes, and cell cycle, as well as to play a variety of roles in managing these processes. TP53 mutations are commonly found in human cancer, including bladder cancer. The TP53 mutation and related pathways may function as bladder cancer driver mutations, promoting disease progression and influencing cancer prognosis and therapeutic strategy. Additionally, mutated TP53 results in the activation of the cancer-related mechanisms, which has an adverse effect on the development of the disease. Numerous studies have shown that a mutant form of the tumor suppressor gene TP53 contributes to the faster spread of metastatic tumor cells. Additionally connected to altered bladder drug and chemotherapy sensitivity is TP53 status. The tumor suppressor gene TP53 can be found on chromosome 17p13. that makes the p53 protein is 1. The gene inhibits the development of tumors by taking part in a number of crucial cellular processes, including cell cycle arrest, differentiation, apoptosis, and DNA damage repair. The majority of TP53 mutations, which are the most common genetic change in cancer, are found in 50% of all cases of human cancer. Despite the fact that mutant p53 has a longer half-life than WT p53 does, the latter accumulates in the nucleus and interacts with oncoproteins to facilitate tumorigenesis.

TP53 mutant high-grade transitional cell bladder cancer (Epidemiology)

Globally, about 275,000 people receive a bladder cancer diagnosis each year, and 108,000 people die from the disease. In developed countries, TCC accounts for 90% of bladder cancer cases. In developing countries, especially those in the Middle East and Africa, SCCs account for the majority of bladder cancer cases, and infection with Schistosoma haematobium is the primary cause of these cancers. Urothelial carcinoma is reportedly the most common urologic cancer in China. The majority of malignant bladder tumors in Africa are SCC, accounting for between two thirds and three quarters of all cases. Schistosomal endemic areas like Sudan and Egypt have the highest incidence of SCC. A few studies from Egypt have recently shown a reversal of this trend due to better schistosomiasis control in the region, whereas in other parts of Africa the association is unchanged. Rising smoking rates are thought to have aided Egypt's transition to TCC, which has a stronger smoking association. In 2022, 81,180 new cases of bladder cancer will be identified in the nation, and 17,100 people will lose their lives to the disease, predicts the American Cancer Society. The likelihood of developing bladder cancer increases with age, and the median age at diagnosis is 73 years old; the illness is rarely identified before the age of 40. Approximately four times as many men than women develop bladder cancer. The male predominance of bladder cancer in the US is a result of transitional cell carcinoma (TCC) being more prevalent in men. The male to female incidence ratio for small cell carcinoma is 1:2, in contrast to TCC. While bladder cancer is not among the top 10 cancers in women, it is the fourth most prevalent cancer in men in the US, after colorectal, lung, and prostate cancer. In 2022, it is predicted that 12,120 men will die from bladder cancer compared to 4980 women. However, the prognosis for women is typically less favorable than for men. Bladder cancer strikes White men in the US twice as often as Black men. However, compared to Whites, Black people have a worse outlook.

TP53 mutant high-grade transitional cell bladder cancer -Current Market Size & Forecast Trends

The market for TP53 mutant high-grade transitional cell bladder cancer is expected to grow significantly, with the overall bladder cancer treatment market valued at around USD 3.9 billion in 2023 and projected to reach approximately USD 5.4 billion by 2034, growing at a CAGR of 3.09%. Cases with TP53 mutations, which are common in high-grade bladder cancer, drive the need for targeted therapies. Advances in personalized medicine and targeted treatments are key factors fueling this growth, particularly in North America, where the incidence of bladder cancer is high. Overall, the market for TP53 mutant high-grade transitional cell bladder cancer is poised for substantial expansion through 2035 as new therapies are developed.

Potential target drugs include mitomycin-C, doxorubicin, and gemcitabine because they are highly sensitive to TP53-mutated bladder cancer cells but not to other types of tumors. Mitomycin-C, doxorubicin, and gemcitabine thus provided the possibility of individualized compounds for bladder cancer patients with TP53 mutations. It's critical to distinguish between bladder cancers (Ta, T1, and carcinoma in situ [CIS]) that are not muscle-invasive and those that are. Each category encompasses both medical and surgical treatment modalities. Guidelines from the National Comprehensive Cancer Network (NCCN) and European Association of Urology (EAU) for non-muscle-invasive cancer strongly suggest stratifying risk of recurrence and progression and using risk tables to determine the best course of treatment. The most effective course of treatment for muscle-invasive bladder cancer is trimodality therapy, which combines radiation therapy and systemic chemotherapy. Radical cystectomy and transurethral resection of bladder tumor (TURBT) are the two main therapeutic options. Low-grade, early-stage patients may benefit from delaying the start of treatment or from a single intravesical chemotherapy injection. The EAU and NCCN guidelines also recommend one immediate chemotherapy instillation as the entirety of adjuvant therapy for patients with a low risk of progression and recurrence. Other intravesical chemotherapies or Bacillus Calmette-Guerin (BCG) immunotherapy may be used for patients with recurrent illness or those at intermediate risk. It is advised for patients at high risk-those with T1-high grade or CIS-to receive intravesical BCG immunotherapy due to the high likelihood of disease progression and recurrence.

Report Highlights

TP53 mutant high-grade transitional cell bladder cancer - Current Market Trends

TP53 mutant high-grade transitional cell bladder cancer - Current & Forecasted Cases across the G8 Countries

TP53 mutant high-grade transitional cell bladder cancer - Market Opportunities and Sales Potential for Agents

TP53 mutant high-grade transitional cell bladder cancer - Patient-based Market Forecast to 2035

TP53 mutant high-grade transitional cell bladder cancer - Untapped Business Opportunities

TP53 mutant high-grade transitional cell bladder cancer - Product Positioning Vis-a-vis Competitors' Products

TP53 mutant high-grade transitional cell bladder cancer - KOLs Insight

Table of Content

1. TP53 mutant high-grade transitional cell bladder cancer Background

  • 1.1. TP53 mutant high-grade transitional cell bladder cancer Definition
  • 1.2. Signs and Symptoms
  • 1.3. Pathogenesis
  • 1.4. Clinical Manifestation
  • 1.5. TP53 mutant high-grade transitional cell bladder cancer biomarkers
  • 1.6. Diagnosis

2. Epidemiology Estimated and Forecast to 2035

  • 2.1. Epidemiology Research Method & Data Sources Used
  • 2.2. United States
    • 2.2.1. Incident Cases of TP53 mutant high-grade transitional cell bladder cancer
    • 2.2.2. Diagnosed and treatable cases of TP53 mutant high-grade transitional cell bladder cancer line of therapies (LOT)
  • 2.3. United Kingdom
    • 2.3.1. Incident Cases of TP53 mutant high-grade transitional cell bladder cancer
    • 2.3.2. Diagnosed and treatable cases of TP53 mutant high-grade transitional cell bladder cancer line of therapies (LOT)
  • 2.4. Spain
    • 2.4.1. Incident Cases of TP53 mutant high-grade transitional cell bladder cancer
    • 2.4.2. Diagnosed and treatable cases of TP53 mutant high-grade transitional cell bladder cancer line of therapies (LOT)
  • 2.5. Germany
    • 2.5.1. Incident Cases of TP53 mutant high-grade transitional cell bladder cancer
    • 2.5.2. Diagnosed and treatable cases of TP53 mutant high-grade transitional cell bladder cancer line of therapies (LOT)
  • 2.6. France
    • 2.6.1. Incident Cases of TP53 mutant high-grade transitional cell bladder cancer
    • 2.6.2. Diagnosed and treatable cases of TP53 mutant high-grade transitional cell bladder cancer line of therapies (LOT)
  • 2.7. Italy
    • 2.7.1. Incident Cases of TP53 mutant high-grade transitional cell bladder cancer
    • 2.7.2. Diagnosed and treatable cases of TP53 mutant high-grade transitional cell bladder cancer line of therapies (LOT)
  • 2.8. Japan
    • 2.8.1. Incident Cases of TP53 mutant high-grade transitional cell bladder cancer
    • 2.8.2. Diagnosed and treatable cases of TP53 mutant high-grade transitional cell bladder cancer line of therapies (LOT)
  • 2.9. China
    • 2.9.1. Incident Cases of TP53 mutant high-grade transitional cell bladder cancer
    • 2.9.2. Diagnosed and treatable cases of TP53 mutant high-grade transitional cell bladder cancer line of therapies (LOT)
  • 2.10. Current Unmet Needs in TP53 mutant high-grade transitional cell bladder cancer

3. Current Treatment Paradigm

  • 3.1. Treatment/Prevention guidelines
  • 3.2. Regulatory Approvals/Indication and Current Benchmarks

4. KOLs Insight (US, EU, JP, CH)

  • 4.1. Unmet Needs
  • 4.2. Analysis of the progress in terms of approvals & current pipeline
  • 4.3. Impact on the treatment algorithm and product positioning
  • 4.4. Relevance of new targets/platforms/ Therapy Uptake Share %
  • 4.5. Physicians Preferences for the new pharmacological agents

5. What's New in 2024/2025

6. Future Treatment Paradigm

  • 6.1. TP53 mutant high-grade transitional cell bladder cancer Competitor Landscape and Approvals Anticipated
  • 6.2. Future Treatment Algorithms and Competitor Positioning
  • 6.3. Key Data Summary for Emerging Treatment

7. Late Phase Therapies Strategic Considerations in TP53 mutant high-grade transitional cell bladder cancer

8. Total Market Forecast

  • 8.1. Key Summary Findings
    • 8.1.1. G8 total Market for TP53 mutant high-grade transitional cell bladder cancer 2022-2035 (USD Million)
    • 8.1.2. G8 total Market for TP53 mutant high-grade transitional cell bladder cancer Therapies 2022-2035 (USD Million)

9. Market Forecast by Country

  • 9.1. United States
    • 9.1.1. United States Market for TP53 mutant high-grade transitional cell bladder cancer 2022-2035 (USD Million)
    • 9.1.2. United States Market for TP53 mutant high-grade transitional cell bladder cancer Therapies 2022-2035 (USD Million)
  • 9.2. Germany
    • 9.2.1. Germany Market for TP53 mutant high-grade transitional cell bladder cancer 2022-2035 (USD Million)
    • 9.2.2. Germany Market for TP53 mutant high-grade transitional cell bladder cancer Therapies 2022-2035 (USD Million)
  • 9.3. France
    • 9.3.1. France Market for TP53 mutant high-grade transitional cell bladder cancer 2022-2035 (USD Million)
    • 9.3.2. France Market for TP53 mutant high-grade transitional cell bladder cancer Therapies 2022-2035 (USD Million)
  • 9.4. Italy
    • 9.4.1. Italy Market for TP53 mutant high-grade transitional cell bladder cancer 2022-2035 (USD Million)
    • 9.4.2. Italy Market for TP53 mutant high-grade transitional cell bladder cancer Therapies 2022-2035 (USD Million)
  • 9.5. Spain
    • 9.5.1. Spain Market for TP53 mutant high-grade transitional cell bladder cancer 2022-2035 (USD Million)
    • 9.5.2. Spain Market for TP53 mutant high-grade transitional cell bladder cancer Therapies 2022-2035 (USD Million)
  • 9.6. United Kingdom
    • 9.6.1. United Kingdom Market for TP53 mutant high-grade transitional cell bladder cancer 2022-2035 (USD Million)
    • 9.6.2. United Kingdom Market for TP53 mutant high-grade transitional cell bladder cancer Therapies 2022-2035 (USD Million)
  • 9.7. Japan
    • 9.7.1. Japan Market for TP53 mutant high-grade transitional cell bladder cancer 2022-2035 (USD Million)
    • 9.7.2. Japan Market for TP53 mutant high-grade transitional cell bladder cancer Therapies 2022-2035 (USD Million)
  • 9.8. China
    • 9.8.1. China Market for TP53 mutant high-grade transitional cell bladder cancer 2022-2035 (USD Million)
    • 9.8.2. China Market for TP53 mutant high-grade transitional cell bladder cancer Therapies 2022-2035 (USD Million)

10. Market Drivers and Barriers

Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!